Canaccord Genuity Initiates Synta Pharmaceuticals At Outperform

Canaccord Genuity initiated coverage on

with a Outperform rating. Synta Pharmaceuticals shares have dropped 43.89% over the past 52 weeks, while the S&P 500 index has gained 15.17% in the same period. Synta Pharmaceuticals shares closed at $2.25 yesterday.